Company History


PreventAGE Health Care, LLC was established in 2012 to providing precise, predictive services to patients, physicians and payers regarding an individual’s risk of developing specific complications associated with diabetes.

The company’s founder and Chief Scientific Officer, Paul Beisswenger, MD, is not only and established medical researcher, but is also a practicing endocrinologist who has been caring for patients with diabetes for more than 35 years. In his clinical practice his observations confirmed the recognized fact that certain patients with diabetes progressed rapidly to develop complications (renal, retinal, cardiovascular, neural) while others progressed slowly or not at all. He hypothesized, and subsequently proved that an individual’s risk of progressing (rapidly, slowly or not at all) could be evaluated by measuring certain biochemical indicators (biomarkers) that are intimately involved with damage and dysfunction at the cellular level. Furthermore, he also reasoned that once an individual’s risk has been determined, a management program specifically tailored to meet that person’s needs can be created. 

The biomarkers that Dr. Beisswenger evaluated were a family of advanced glycation end-products (AGEs) and oxidative products (OPs). Over the course of ten years, Dr. Beisswenger and his team at Dartmouth-Hitchcock Medical Center developed highly sensitive and specific methods to identify and quantify the biomolecules of interest.

In a major diagnostic breakthrough new biomarkers for early prediction of diabetic kidney disease were identified and verified in both Type 1 and 2 populations using landmark outcome studies including the Natural History of Diabetes Study, the Pima Kidney Disease Study and DCCT/EDIC. Based on years of hypothesis-driven innovative research on the role of selective activation of precursor chemical pathways in susceptibility to diabetic complications, Dr. Beisswenger and his team completed studies showing that three specific plasma AGE biomarkers are significantly higher in biopsy documented rapid diabetic nephropathy progressors (RP) than in slow progressors.  Subsequent studies have identified and validated biomarkers for the risk of cardiovascular disease in the DCCT/EDIC, VADT, and the ACCORD studies.

Dr. Beisswenger connected with seasoned industry executives and investors to begin building an avenue by which the benefits of his research could reach the diabetes community. Mark Carvlin, Ph.D, a veteran of the life sciences industry, joined Dr. Beisswenger in 2011 to help create the framework for the company and to run operations. After recruiting a small team of experienced and dedicated professionals, PreventAGE Health Care LLC was incorporated in 2012.

PreventAGE operates out of its state-of-the-art, CLIA certified laboratory at the Dartmouth Regional Technology Center in Lebanon, New Hampshire. The team has used this facility to test samples provided by key collaborators around the world. PreventAGE’s network of collaborators continues to grow, allowing the team access to samples from a broad set of landmark scientific studies.



Since its founding PreventAGE Health Care has achieved the following  series of key milestones leading to success.



–      Completed "Natural History of Diabetic Nephropathy Study" (Type 1 diabetes patient population) and published results on  prediction of kidney disease in Diabetes Care and Amino Acids Journal

–      Formed PreventAGE Health Care

–      Established lab operations and infrastructure at Dartmouth Regional Technology Center

–      Seed funding procured



–      Achieved agreement to test predictive value of our biomarkers in the "Pima Indian Clinical Trial of Diabetic Kidney Disease" (Type 2 diabetes patient population)

–      Received samples from the Pima trial for analysis

–      Secured intellectual property with multiple patent applications

–      Awarded SBIR Fast Track Grant

-       Upgraded LC/triple quadrupole mass spectrometric methods and analyzed ~ 16,000 samples 

–      Received samples from the DCCT/EDIC clinical trial  (Type 1 diabetes patient population)



–      Received CLIA Certification as LDT diagnostic laboratory

–      Developed pipeline of clients to supply more than 50,000 samples

–      Developed independent economic analysis with Global Market Access Solutions (GMAS) to evaluate the likely impact of our diagnostic on renal and cardiovascular outcomes in the healthcare system          

–      Presented additional Pima renal data at IMARS conference in Tokyo

–      Completed Pima analyses showing that AGEs predict diabetic kidney disease and published results in Diabetes




–      Refined proprietary algorithms for type 1 diabetes and finalized reporting parameters

–      COMPASS T1 report established

–      Defined clinical utility profile

–      Submitted NIH/SBIR CRP grant

–      Studied clinical and sub-clinical cardiovascular outcomes in Veterans Affairs Diabetes Trial (VADT) and   showed  predictive value of oxidative stress markers in type 2 diabetes.

–      Presented VADT cardiovascular outcomes at 76th annual meeting of ADA and published results in Diabetes Care.



–      Refined proprietary Algorithms for Type 2 diabetes, and finalized reporting parameters for COMPASS T2 report.

–      Analysis of DCCT/EDIC samples confirmed strong predictive power of Oxidative stress markers for cardiovascular disease.

–       Published VADT data on sub-clinical CVD and oxidative products in Diabetes Care

–      Presented DCCT/EDIC CV data at 77th annual ADA meeting

–      Increased throughput and capacity of LC mass spectrometry analyses



–      Present additional data on predictive value of oxidative products for metabolic syndrome, high risk lipid profiles, and inflammation in two major type 2 diabetes trials at World Congress on Insulin Resistance Diabetes & Cardiovascular Disease  (awarded gold medal)

–      Published data on VADT/ACCORD CVD endpoints and oxidation products in Diabetes Care

–      Presented at 78th Annual Meeting of ADA- "AGEs predict diabetic kidney disease in DCCT/EDIC and confirm findings in two other trials"


We are excited about our success to date and foresee continued growth as we provide new predictive tests for a medical care system that will increasingly focus on prevention rather than reactive intervention alone.